NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationPRNewsWire • 08/30/24
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PricePRNewsWire • 08/07/24
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialPRNewsWire • 08/01/24
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionPRNewsWire • 07/09/24
This cheap biotech offers investors a play on ALS if trial data continues to impressMarket Watch • 07/02/24
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugPRNewsWire • 07/01/24
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsPRNewsWire • 06/24/24
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitPRNewsWire • 05/20/24
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningPRNewsWire • 05/14/24
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsPRNewsWire • 05/07/24
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseasePRNewsWire • 04/22/24
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingPRNewsWire • 04/18/24
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024PRNewsWire • 04/12/24
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementPRNewsWire • 04/10/24
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsPRNewsWire • 04/09/24
NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdatePRNewsWire • 04/05/24
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialPRNewsWire • 02/21/24
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024Accesswire • 01/30/24
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsPRNewsWire • 01/09/24
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementPRNewsWire • 12/27/23
“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS TrialMCAP MediaWire • 12/15/23
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialPRNewsWire • 12/14/23